Twist Bioscience (TWST) CEO sells 16,470 shares under 10b5-1 plan

Rhea-AI Filing Summary

Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported a combination of option exercise and share sales in common stock. She exercised employee stock options to acquire 16,470 shares at an exercise price of $8.82 per share, then sold 16,470 shares in multiple open‑market transactions at prices ranging from $65.3256 to $68.6141 per share. After these transactions, she directly owns 861,860 shares of Twist common stock. The sales were carried out under a pre‑arranged Rule 10b5-1 trading plan adopted on May 27, 2025.

Insider Trade Summary 10b5-1

Net Seller: 16,470 shares ($1,118,555)

Net Sell 10 txns

Insider Leproust Emily M.

Role Chief Executive Officer

Sold 16,470 shs ($1.12M)

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (right to buy)	16,470	$0.00	--
Exercise	Common Stock	16,470	$8.82	$145K
Sale	Common Stock	1,482	$65.3256	$97K
Sale	Common Stock	900	$66.8477	$60K
Sale	Common Stock	7,623	$67.9508	$518K
Sale	Common Stock	6,465	$68.6141	$444K
holding	Employee Stock Option (right to buy)	--	--	--
holding	Employee Stock Option (right to buy)	--	--	--
holding	Employee Stock Option (right to buy)	--	--	--
holding	Employee Stock Option (right to buy)	--	--	--

Holdings After Transaction: Employee Stock Option (right to buy) — 75,439 shares (Direct, null); Common Stock — 863,342 shares (Direct, null)

Footnotes (1)

1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025. Represents the weighted average sales price per share. The shares sold at prices ranging from $65.00 to $65.820 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Represents the weighted average sales price per share. The shares sold at prices ranging from $66.240 to $67.210 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Represents the weighted average sales price per share. The shares sold at prices ranging from $67.240 to $68.2375 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Represents the weighted average sales price per share. The shares sold at prices ranging from $68.240 to $69.190 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria. The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.

Key Figures

Shares sold: 16,470 shares Sale prices: $65.3256–$68.6141 per share Options exercised: 16,470 shares at $8.82/share +3 more

6 metrics

Shares sold 16,470 shares Open-market sales on May 28, 2026

Sale prices $65.3256–$68.6141 per share Reported weighted average prices for sales

Options exercised 16,470 shares at $8.82/share Employee stock option exercise into common stock

Post-transaction holdings 861,860 shares Common stock directly owned after transactions

Remaining option grant 64,950 underlying shares at $67.85 Employee stock option expiring August 31, 2030

10b5-1 plan adoption May 27, 2025 Date Rule 10b5-1 trading plan was adopted

Key Terms

Rule 10b5-1 trading plan, Employee Stock Option (right to buy), weighted average sales price per share, performance stock options, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted..."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Employee Stock Option (right to buy) financial

"security_title: "Employee Stock Option (right to buy)" with underlying security title Common Stock"

weighted average sales price per share financial

"Represents the weighted average sales price per share. The shares sold at prices ranging..."

performance stock options financial

"Represents performance stock options granted to the reporting person on September 1, 2020..."

derivative exercise/conversion financial

"transaction_action: "derivative exercise/conversion" for the M code transactions"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Leproust Emily M.

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD.

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/28/2026		M(1)		16,470	A	$8.82	863,342	D
Common Stock	05/28/2026		S(1)		1,482	D	$65.3256(2)	861,860	D
Common Stock	05/28/2026		S(1)		900	D	$66.8477(3)	860,960	D
Common Stock	05/28/2026		S(1)		7,623	D	$67.9508(4)	853,337	D
Common Stock	05/28/2026		S(1)		6,465	D	$68.6141(5)	846,872	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$5.95							(6)	09/28/2025	Common Stock	0		0	D
Employee Stock Option (right to buy)	$26.66							(7)	11/18/2028	Common Stock	0		266,539	D
Employee Stock Option (right to buy)	$23.33							(8)	10/23/2029	Common Stock	0		131,290	D
Employee Stock Option (right to buy)	$67.85							12/19/2022	08/31/2030	Common Stock	64,950		64,950(9)	D
Employee Stock Option (right to buy)	$8.82	05/28/2026		M			16,470	(10)	09/28/2027	Common Stock	16,470	$0	75,439	D

Explanation of Responses:

1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 27, 2025.

2. Represents the weighted average sales price per share. The shares sold at prices ranging from $65.00 to $65.820 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

3. Represents the weighted average sales price per share. The shares sold at prices ranging from $66.240 to $67.210 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

4. Represents the weighted average sales price per share. The shares sold at prices ranging from $67.240 to $68.2375 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

5. Represents the weighted average sales price per share. The shares sold at prices ranging from $68.240 to $69.190 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

6. The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.

7. 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.

8. 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.

9. Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.

10. The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Emily M. Leproust	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

How many Twist Bioscience (TWST) shares did CEO Emily Leproust sell in this Form 4?

Emily Leproust sold 16,470 shares of Twist Bioscience common stock. The Form 4 shows four open‑market sale transactions totaling 16,470 shares, with reported prices between $65.3256 and $68.6141 per share on May 28, 2026.

What stock options did Twist Bioscience (TWST) CEO Emily Leproust exercise?

She exercised employee stock options for 16,470 shares at $8.82 per share. The exercised options were "Employee Stock Option (right to buy)" awards, converting into 16,470 shares of Twist Bioscience common stock in a derivative exercise transaction.

How many Twist Bioscience (TWST) shares does CEO Emily Leproust own after the reported transactions?

After the reported transactions, Emily Leproust directly owns 861,860 shares. The final non‑derivative transaction line in the Form 4 shows total shares following the last transaction as 861,860 shares of Twist Bioscience common stock held directly.

Were Emily Leproust’s Twist Bioscience (TWST) share sales under a Rule 10b5-1 trading plan?

Yes. The Form 4 states the transactions were under a Rule 10b5-1 plan. A footnote explains the reported trades were effected pursuant to a Rule 10b5‑1 trading plan that Emily Leproust previously adopted on May 27, 2025.

What remaining stock options does Twist Bioscience (TWST) CEO Emily Leproust hold?

She holds an option covering 64,950 underlying shares at $67.85 per share. The derivative holdings table shows an employee stock option, exercisable for 64,950 shares of common stock, with a August 31, 2030 expiration date.

What were the price ranges for Emily Leproust’s Twist Bioscience (TWST) stock sales?

The reported sales occurred between about $65.3256 and $68.6141 per share. Individual sale lines show weighted average prices of $65.3256, $66.8477, $67.9508, and $68.6141 per share for the open‑market transactions.